Skip to Main Content

Author Details

Carlos Caldas
Cancer Research UK Cambridge Institute, University of Cambridge
1992
476
115
Trey Ideker (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
37499655FOXC2 promotes vasculogenic mimicry and resistance to anti-angiogenic therapy.Cell Rep2023
37479706Obesity-associated changes in molecular biology of primary breast cancer.Nat Commun2023
37790315Prediction of cancer treatment response from histopathology images through imputed transcriptomics.Res Sq2023
34256129Clinical interpretation of whole-genome and whole-transcriptome sequencing for precision oncology.Semin Cancer Biol2022
35772352Germline allelic expression of genes at 17q22 locus associates with risk of breast cancer.Eur J Cancer2022
35709760eQTL Set-Based Association Analysis Identifies Novel Susceptibility Loci for Barrett Esophagus and Esophageal Adenocarcinoma.Cancer Epidemiol Biomarkers Prev2022
35437329Breast tumor microenvironment structures are associated with genomic features and clinical outcome.Nat Genet2022
35425960Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification.Cancer Res2022
36480778Implementation of Whole-Genome and Transcriptome Sequencing Into Clinical Cancer Care.JCO Precis Oncol2022
36779025Applicability of Blockchain-Based Implementation for Risk Management in Healthcare Projects.Blockchain Healthc Today2022
36071033High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER<sup>+</sup> breast cancer.Nat Commun2022
35868265The impact of AI on research.Cell2022
35864159Copy number heterogeneity identifies ER+ breast cancer patients that do not benefit from adjuvant endocrine therapy.Br J Cancer2022
35921524Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance.Clin Cancer Res2022
36289203Clonal somatic copy number altered driver events inform drug sensitivity in high-grade serous ovarian cancer.Nat Commun2022
36376977Androgen receptor function and targeted therapeutics across breast cancer subtypes.Breast Cancer Res2022
36376284Author Correction: High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER<sup>+</sup> breast cancer.Nat Commun2022
35290781With one eye on the future.Cancer Cell2022
35278078Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation.Oncologist2022
34875674Multi-omic machine learning predictor of breast cancer therapy response.Nature2022
34902335Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients.Lancet Oncol2022
35196484Nucleoporin-93 reveals a common feature of aggressive breast cancers: robust nucleocytoplasmic transport of transcription factors.Cell Rep2022
34703030Clonal populations of a human TNBC model display significant functional heterogeneity and divergent growth dynamics in distinct contexts.Oncogene2022
34175442Clinical utility of whole-genome sequencing in precision oncology.Semin Cancer Biol2022
34119643Analytical demands to use whole-genome sequencing in precision oncology.Semin Cancer Biol2022
32723485Optimising the Duration of Adjuvant Trastuzumab in Early Breast Cancer in the UK.Clin Oncol (R Coll Radiol)2021
33686070Time-resolved single-cell analysis of Brca1 associated mammary tumourigenesis reveals aberrant differentiation of luminal progenitors.Nat Commun2021
33893315Characterisation of PALB2 tumours through whole-exome and whole-transcriptomic analyses.NPJ Breast Cancer2021
33932331Deciphering the signaling network of breast cancer improves drug sensitivity prediction.Cell Syst2021
33723394PI3K activation promotes resistance to eribulin in HER2-negative breast cancer.Br J Cancer2021
33579347FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1.Breast Cancer Res2021
34762647Positive correlation between transcriptomic stemness and PI3K/AKT/mTOR signaling scores in breast cancer, and a counterintuitive relationship with PIK3CA genotype.PLoS Genet2021
34518533DNA methylation landscapes of 1538 breast cancers reveal a replication-linked clock, epigenomic instability and cis-regulation.Nat Commun2021
34158398TSHZ2 is an EGF-regulated tumor suppressor that binds to the cytokinesis regulator PRC1 and inhibits metastasis.Sci Signal2021
33963313Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment.Cell Death Differ2021
34099718The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers.NPJ Breast Cancer2021
34120626High-throughput surface marker screen on primary human breast tissues reveals further cellular heterogeneity.Breast Cancer Res2021
342894373D deformable registration of longitudinal abdominopelvic CT images using unsupervised deep learning.Comput Methods Programs Biomed2021
34254730Functional genomics approaches to improve pre-clinical drug screening and biomarker discovery.EMBO Mol Med2021
34189473Metabolic imaging with hyperpolarized [1-<sup>13</sup>C] pyruvate in patient-derived preclinical mouse models of breast cancer.STAR Protoc2021
33423300Germline APOBEC3B deletion increases somatic hypermutation in Asian breast cancer that is associated with Her2 subtype, PIK3CA mutations and immune activation.Int J Cancer2021
33413557NRG1 fusions in breast cancer.Breast Cancer Res2021
32770247Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy.J Natl Cancer Inst2021
31560077Fbxl17 is rearranged in breast cancer and loss of its activity leads to increased global O-GlcNAcylation.Cell Mol Life Sci2020
35122040Cancer-associated fibroblast compositions change with breast cancer progression linking the ratio of S100A4<sup>+</sup> and PDPN<sup>+</sup> CAFs to clinical outcome.Nat Cancer2020
35121983Age-correlated protein and transcript expression in breast cancer and normal breast tissues is dominated by host endocrine effects.Nat Cancer2020
31756444Association Between Levels of Sex Hormones and Risk of Esophageal Adenocarcinoma and Barrett's Esophagus.Clin Gastroenterol Hepatol2020
31964840Imaging breast cancer using hyperpolarized carbon-13 MRI.Proc Natl Acad Sci U S A2020
31949161A network analysis to identify mediators of germline-driven differences in breast cancer prognosis.Nat Commun2020
32005967Author Correction: ARID1A influences HDAC1/BRD4 activity, intrinsic proliferative capacity and breast cancer treatment response.Nat Genet2020
  • 1 - 50 of 476

Recommended Authors

Darragh G McArt
Queen's University Belfast
Career Start Year 2009
Number of shared co-authors 5
Gabriele Zoppoli
University of Genoa and Ospedale Policlinico San Martino
Career Start Year 2008
Number of shared co-authors 18
Salvatore Piscuoglio
University of Basel
Career Start Year 2008
Number of shared co-authors 8
Ritu Roy
University of California San Francisco.
Career Start Year 2007
Number of shared co-authors 6
Nicola Waddell
QIMR Berghofer Medical Research Institute
Career Start Year 2006
Number of shared co-authors 74
Caterina Marchi??
University of Turin, Candiolo Cancer Institute, FPO-IRCCS
Career Start Year 2005
Number of shared co-authors 9
Joshy George
Peter MacCallum Cancer Centre
Career Start Year 2005
Number of shared co-authors 61
Katherine A Hoadley
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill
Career Start Year 2004
Number of shared co-authors 59
Obi L Griffith
Washington University
Career Start Year 2003
Number of shared co-authors 43
Leslie Cope
Johns Hopkins University School of Medicine
Career Start Year 2003
Number of shared co-authors 15
Peter Horak
German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT)
Career Start Year 2003
Number of shared co-authors 11
Michael Slifker
Fox Chase Cancer Center
Career Start Year 2002
Number of shared co-authors 2
Siddhartha Deb
Olivia Newton-John Cancer Research Institute
Career Start Year 2002
Number of shared co-authors 4
Joel S Parker
Lineberger Cancer Center, University of North Carolina
Career Start Year 2002
Number of shared co-authors 41
Britta Weigelt
Memorial Sloan Kettering Cancer Center
Career Start Year 2002
Number of shared co-authors 41
Syed Haider
Institute of Cancer Research
Career Start Year 2002
Number of shared co-authors 48
Maryou B Lambros
The Institute of Cancer Research
Career Start Year 2002
Number of shared co-authors 18
Richard B Schwab
Department of Medicine and Moores Cancer Center, University of California San Diego
Career Start Year 2000
Number of shared co-authors 8
Luciano G Martelotto
Monash University
Career Start Year 2000
Number of shared co-authors 6
Tobias Sj??blom
Uppsala University
Career Start Year 1999
Number of shared co-authors 4
Ingrid Hedenfalk
Lund University and Skane University Hospital
Career Start Year 1997
Number of shared co-authors 26
Benedikt Brors
German Cancer Research Center (DKFZ)
Career Start Year 1997
Number of shared co-authors 52
Jan Budczies
Institute of Pathology, University Hospital Heidelberg
Career Start Year 1996
Number of shared co-authors 12
Susan J Done
University Health Network
Career Start Year 1994
Number of shared co-authors 8
Adam B Olshen
12224University of California san francisco
Career Start Year 1993
Number of shared co-authors 20
Ben Ho Park
Vanderbilt University Medical Center
Career Start Year 1990
Number of shared co-authors 19
Jonathan R Pollack
Stanford University School of Medicine
Career Start Year 1987
Number of shared co-authors 18
Olli Kallioniemi
Karolinska Institute
Career Start Year 1984
Number of shared co-authors 53
Edison T Liu
USA The Jackson Laboratory Cancer Center
Career Start Year 1982
Number of shared co-authors 16
Jeffrey S Ross
Foundation Medicine
Career Start Year 1974
Number of shared co-authors 14

Collaborators

Paul D P Pharoah
Center for Cancer Genetic Epidemiology, University of Cambridge
Co-authored papers 85
Oscar M Rueda
University of Cambridge
Co-authored papers 72
Samuel Aparicio
University of British Columbia
Co-authored papers 52
James D Brenton
CRUK Cambridge Institute, University of Cambridge
Co-authored papers 37
Alejandra Bruna
CRUK Cambridge Institute, University of Cambridge
Co-authored papers 36
Andrew E Teschendorff
UCL Cancer Institute, University College London
Co-authored papers 32
Anne-Lise B??rresen-Dale
Institute for Cancer Research, Oslo University Hospital
Co-authored papers 28
David G Huntsman
University of British Columbia
Co-authored papers 27
Janet A Dunn
Warwick Clinical Trials Unit, University of Warwick
Co-authored papers 25
Christina Curtis
Stanford University School of Medicine
Co-authored papers 21
Stephen-John Sammut
Co-authored papers 19
Douglas F Easton
University of Cambridge
Co-authored papers 19
F??tima Carneiro
Centro Hospitalar Universitario de Sao Joao.
Co-authored papers 17
Laura J Van't Veer
University of California San Francisco
Co-authored papers 16
Vessela N Kristensen
Faculty of Clinical Medicine, University of Oslo
Co-authored papers 15
Alison M Dunning
Co-authored papers 15
Mark J Dunning
The Medical School, The University of Sheffield
Co-authored papers 14
Hans Kristian Moen Vollan
F Hoffmann-La Roche Ltd
Co-authored papers 13
Sohrab P Shah
Memorial Sloan Kettering Cancer Center
Co-authored papers 13
Carla Oliveira
Co-authored papers 12
Montserrat Garcia-Closas
National Cancer Institute
Co-authored papers 12
Jason S Carroll
Co-authored papers 12
John W M Martens
Erasmus Medical Center (MC) Cancer Institute
Co-authored papers 12
Fergus J Couch
Mayo Clinic
Co-authored papers 12
Anna H Wu
University of Southern California
Co-authored papers 12
John M S Bartlett
University of Edinburgh
Co-authored papers 11
Javier Ben??tez
Instituto de Salud Carlos III
Co-authored papers 10
Stephen J Chanock
National Cancer Institute, National Institutes of Health
Co-authored papers 10
Jonine D Figueroa
The Usher Institute, The University of Edinburgh
Co-authored papers 10
Jos Jonkers
Oncode Institute, Netherlands Cancer Institute
Co-authored papers 10
Release 1.2